Laverock Therapeutics secures Innovate UK funding
Summary
Laverock Therapeutics secures \xa31m funding via the Innovate UK Investor Partnerships Future Economy programme, supported by UKI2S.Laverock Therapeutics, developer of a unique gene silencing platform for the creation of programmable advanced therapies, is pleased to announce that it has been awarded \xa31m in funding, made up of a \xa3700k grant from Innovate UK, the UKs innovation agency, and supported by co-funding from the UK Innovation and Science Seed Fund (UKI2S) through the Investor Partnerships Programme. The award will enable Laverock to progress its immune effector cell therapeutic programme aiming to combat hard-to-treat cancers, via use of its gene editing induced gene silencing (GEiGS\xae) technology.The Innovate UK and UKI2S funded project will provide access to patient derived, highly disease relevant experimental tools. These collaborations will focus on patients needs and enable the development of more targeted therapeutic products for the communities that will benefit.Tim Allsopp, Chief Technology Officer of Laverock Therapeutics, said, Were tremendously excited by this achievement and the public-private endorsement of our technology that Innovate co-funding provides. Wed like to thank Innovate UK and UKI2S for their support and look forward to integrating our novel gene silencing GEiGS\xae platform into more effective therapeutic designs for the benefit of the global cancer patient community.Oliver Sexton, UKI2S Investment Director, added, UKI2S is delighted to invest alongside Innovate UK as a member of the Investor Partnerships scheme. As an investor, Innovate UKs support for additional programmes provides a powerful tool to accelerate development and de-risk investment.